Next-Generation Genetic Medicine Delivery

We develop next generation nucleic acid-based therapies using our Fusogenix genetic medicines delivery platform.

Fusogenix uses a novel mechanism of action to deliver nucleic acids, intact and unmodified, directly into the cytosol of target cells. The technology is applicable to a wide range of genetic medicines.


We are dedicated to developing a safe and effective Fusogenix DNA vaccine to protect against COVID-19.

April 15, 2021 - The first recruits were dosed to start the Phase I trial of Entos’ made-in-Canada COVID-19 DNA vaccine, Covigenix VAX-001! The Canadian Center for Vaccinology in Halifax, Nova Scotia is conducting the trial.

Like the globally approved mRNA vaccines, Entos’ DNA vaccine delivers the information needed for our cells to make the spike protein to stimulate a protective immune response against SARS-CoV-2. However, Entos’ Covigenix DNA vaccine is more stable at fridge and room temperatures and easier to upscale and manufacture millions of doses.

“We need to get 16 billion doses worldwide to beat this pandemic, and we believe DNA is the perfect way to approach that,” said John Lewis, CEO Entos Pharmaceuticals.

Go to the News tab to read more about Entos and DNA vaccines.

Enabling tomorrow’s Nanomedicines

Fusogenix is the ideal platform for delivery of next generation genetic therapies.

Unlike conventional lipid-based delivery, Fusogenix is well tolerated at high systemic doses, and retains maximal activity with repeat dosing. Entos has developed unique formulations to effectively deliver a wide range of genetic therapies, including gene therapy, mRNA, miRNA, RNAi, and CRISPR.


Delivery of nanomedicines throughout the body

Fusogenix has a wide biodistribution across all organs and tissues.

Due to the unique biophysical and chemical properties of Fusogenix, a wide variety of extra-hepatic tissues can be effectively targeted at therapeutic doses. Entos has developed a panel of formulations to accurately target specific tissues.

Intracellular Delivery by Direct Fusion

Fusogenix uses a novel fusion mechanism to deliver its payload directly inside cells.

Our proprietary FAST (Fusion-Associated Small Transmembrane) protein technology enables fusion of the proteo-lipid vehicle with the plasma membrane of target cells. Nucleic acid cargoes are delivered intact into the cytoplasm for immediate use as a therapeutic agent.

Entos Pharmaceuticals
Unit 4550, 10230 Jasper Avenue
Edmonton, Alberta, Canada
T5J 4P6

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.